Oscient gains expanded global rights to ramoplanin
Massachusetts, USA-based Oscient Pharmaceuticals and Pfizer subsidiary Vicuron Pharmaceuticals have restructured the business relationship for the former's lead clinical candidate, ramoplanin, a novel glycolipodepsipeptide antibiotic currently in development for the potential treatment of Clostridium difficile-associated disease.
The disease generates an estimated $1.1 billion in hospital health costs annually in the USA and can prolong hospital stays by one to three days.
As part of the new arrangement, Oscient, which previously licensed ramoplanin from Vicuron for the USA and Canada only, acquired worldwide rights and assumes full control of the drug's manufacturing, development and commercialization on a global basis. Oscient recently agreed on a Special Protocol Assessment with the US Food and Drug Administration for the Phase III program for ramoplanin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze